Voyageur Pharmaceuticals Ltd.
VYYRF · OTC
8/31/2025 | 5/31/2025 | 2/28/2025 | 11/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.08 | 0.28 | -0.12 | -0.01 |
| FCF Yield | -3.20% | -1.18% | -5.79% | 20.78% |
| EV / EBITDA | -20.48 | -40.05 | -28.43 | -0.58 |
| Quality | ||||
| ROIC | -87.17% | -56.24% | -65.91% | -89.41% |
| Gross Margin | -3,346.43% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.68 | 0.48 | 1.69 | -0.18 |
| Growth | ||||
| Revenue 3-Year CAGR | 200,162.99% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -146.49% | 81.09% | -1,799.33% | 832.98% |
| Safety | ||||
| Net Debt / EBITDA | 0.69 | 0.62 | 0.73 | 0.27 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 2.49 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 36.15 | 0.00 | 0.00 | 0.00 |